What’s Your Healthcare and Lifesciences Playbook? Key Insights from Industry Leaders on Scaling Growth Strategies in 2026

After several years of recovery and reinvention, healthcare and life sciences is entering a phase where growth will be defined less by experimentation and more by execution at scale. The industry is no longer debating whether AI, genomics, or consumer‑centric care will matter. The more difficult question now is which of these innovations can be operationalized, reimbursed, and sustained under mounting regulatory, financial, and workforce pressure.

These realities framed Frost & Sullivan’s Growth Webinar, The 2026 Healthcare and Life Sciences Playbook: Growth Opportunities Reshaping the Industry, where industry leaders examined what will actually drive growth and what could quietly derail it over the next 12-24 months.

The session brought together leading Growth Experts from the industry:

Click here to access the discussion’s recording.

Additionally, click here to explore our comprehensive analysis of emerging opportunities in the Healthcare and Life Sciences industry.

During the webinar, panelists focused on the practical levers of growth and the constraints that will define competitive success across the healthcare and life sciences ecosystem. Highlights include:

AI Is Scaling but Only Where It Fits Clinical and Economic Reality

Artificial intelligence has moved decisively beyond pilots. Hospitals are deploying AI across clinical documentation, imaging triage, workflow automation, and decision support. Pharmaceutical companies are gaining strategic value by embedding AI into clinical development and manufacturing workflows. However, the discussion made one point clear: AI adoption is not driven by novelty, it is driven by validation.

Solutions gaining traction share three characteristics:

• Regulatory credibility, including approvals by the US Food and Drug Administration (FDA)
• Economic viability, with clear reimbursement pathways such as CMS coverage
• Minimal disruption to existing clinical workflows

Tools that add steps, screens, or cognitive burden struggle to scale. Those that quietly remove friction, saving clinician time and improving consistency, are becoming embedded into day‑to‑day operations.

Multi‑omics Data Is Abundant; Insights Are Not

Multi‑omics data generated at unprecedented speed and volume provides unprecedented insights into drug response, and personalized treatment optimization. Thousands of omics‑enabled clinical trials launch every year, and molecular data is increasingly part of routine care.

Yet the competitive gap is widening between organizations that accumulate data and those that operate it. Panelists emphasized that value now comes from the ability to:

• Query across multiple trials and cohorts
• Reuse molecular data beyond a single study or indication
• Combine omics data with clinical and real‑world datasets

In early‑stage drug discovery, AI‑driven analysis of multi‑omics data is helping reduce trial risk, refine patient selection, and accelerate target discovery but only where data foundations are mature enough to support it.

Value‑based Care Is Moving into High‑cost Specialties

Value‑based care is no longer confined to primary care models. Panelists highlighted its growing influence in oncology, cardiology, and neurology, areas where outcomes, costs, and complexity intersect most sharply.

As reimbursement becomes increasingly tied to results, healthcare organizations are rethinking how technology supports clinical decision‑making, data integration, and outcome measurement. This shift is reshaping purchasing decisions and care pathways across both routine and tertiary care settings.

Consumerization Is Redefining Where Care Begins

Demand for at‑home and “anywhere, anytime” diagnostics continues to rise as patients demand convenience, and cost pressures push payers toward lower-acuity settings. Patients are no longer passive recipients of care, they are combining diagnostic results, wearable data, and AI tools to guide everyday decisions, often before engaging the traditional healthcare system.

For companies operating in this space, success depends less on demand creation and more on execution. Flexibility in product design, mobile‑first architectures, and regulatory agility are becoming essential as policies and consumer expectations continue to evolve.

Don’t stop here! The Growth Webinar also highlights the critical shifts that will shape your 2026 healthcare and life sciences strategy:

Additionally, click here to explore our comprehensive analysis of emerging opportunities in the Healthcare and Life Sciences industry.